medigraphic.com

2023, Number 3

<< Back Next >>

Rev Hematol Mex 2023; 24 (3)

Detection of FLT3-ITD and its role in the diagnosis of pediatric patients with acute myeloid leukemia

Ramírez MEC, Ortiz GVM, Aguilar EDV, Vega VML, Garay SSA

Language: Spanish
References: 16
Page: 136-144
PDF size: 279.63 Kb.


ABSTRACT

Objective: To implement the detection of FLT3-ITD in pediatric patients with acute myeloid leukemia.
Materials and Methods: A retrospective study performed from 2016 to 2020 in which we detail the PCR technique followed by capillary electrophoresis; showing the validation strategy of the trial and our experience in the use of this technique in 14 bone marrow samples of pediatric patients.
Results: We showed that it is an accuracy, robust and precise method, detecting a sensitivity of the test of an allelic radius (AR) of 0.01 ± 0.001. We observed an incidence of the mutation FLT3-ITD of 14.3% with acute myeloid leukemia that also had t(15;17)(q22; q12).
Conclusions: This technique can be reproduced in other molecular diagnostic centers, helping the doctor in the risk stratification, monitoring, treatment and prognosis of the patient with acute myeloid leukemia.


REFERENCES

  1. Murphy KM, Hafez MJ, Smith BD, Cooper LC, Berg KD.Detection of FLT3 internal tandem duplication and D835mutations by a multiplex polymerase chain reaction andcapillary electrophoresis assay. J Mol Diagnostics 2003; 5:96-102. doi: 10.1016/S1525-1578(10)60458-8.

  2. Sexauer AN, Tasian SK. Targeting FLT3 signaling in childhoodacute myeloid leukemia. Front Pediatr 2017; 5: 1-9.

  3. Sakaguchi M, Nakajima N, Yamaguchi H, Najima Y, et al.The sensitivity of the FLT3-ITD detection method is animportant consideration when diagnosing acute myeloidleukemia. Leuk Res Reports 2020; 13: 100198. doi:10.1016/j.lrr.2020.100198.

  4. Cuervo-Sierra J, Jaime-Pérez JC, Gómez-Almaguer D. Mutacionesdel módulo FLT3 en leucemia aguda mieloblástica.Rev Hematol Mex 2012; 13: 177-184.

  5. Molina-Garay C, Carrillo-Sánchez K, Flores-Lagunes LL,Jiménez-Olivares M, et al. Profiling FLT3 mutations inMexican acute myeloid leukemia pediatric patients: impacton overall survival. Front Pediatr 2020; 8.

  6. Burnatt G, Licinio M, Gaspar P, Schveitzer A, et al. Analysisof the presence of FLT3 gene mutation and associationwith prognostic factors in adult and pediatric acute leukemiapatients. Braz J Pharm Sci 2017; 53: 1-11. https://doi.org/10.1590/s2175-97902017000216105.

  7. Levis MJ, Perl A, Altman JK, Gocke CD, et al. A next-generationsequencing-based assay for minimal residual disease assessmentin AML patients with FLT3-ITD mutations. Blood Adv2018; 2: 825-831. doi: 10.1182/bloodadvances.2018015925.

  8. Cucchi DGJ, Denys B, Kaspers G, Janssen J, et al. RNA-basedFLT3-ITD allelic ratio is associated with outcome and ex vivoresponse to FLT3 inhibitors in pediatric AML. Blood 2018;131: 2485-2489. doi: 10.1182/blood-2017-12-819508.

  9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al. WHO Classificationof Tumours of Haematopoietic and Lymphoid Tissues.Lyon, France. World Health Organization Classification ofTumours of Haematopoietic and Lymphoid Tissue 4th, 2017.

  10. Wu X, Feng X, Zhao X, Ma F, et al. Prognostic significanceof FLT3-ITD in pediatric acute myeloid leukemia: a metaanalysisof cohort studies. Mol Cell Biochem 2016; 420:121-128. doi: 10.1007/s11010-016-2775-1.

  11. Schnittger S, Bacher U, Haferlach C, Kern W, et al. Clinicalimpact of FLT3 mutation load in acute promyelocyticleukemia with t(15;17)/PML-RARA. Haematologica 2011;96: 1799-1807.

  12. Cuervo-Sierra J, Jaime-Pérez JC, Martínez-Hernández RA,García-Sepúlveda RD, et al. Prevalence and clinical significanceof FLT3 mutation status in acute myeloid leukemia patients intwo Latin American countries: A multicenter study. Arch MedRes 2016; 47: 172-179. doi: 10.1016/j.arcmed.2016.06.003.

  13. Rasekh EO, Elsayed GM, Madney Y, El Gammal MM. Prognosticsignificance of bcr-1 and bcr-3 isoforms of PML-RARAand FLT3-ITD in patients with acute promyelocytic leukemia.Clin Lymphoma Myeloma Leuk 2020; 20: 156-167.doi: 10.1016/j.clml.2019.08.006.

  14. Kottaridis PD, Gale RE, Frew ME, Harrison G, et al. The presenceof a FLT3 internal tandem duplication in patients withacute myeloid leukemia (AML) adds important prognosticinformation to cytogenetic risk group and response to the firstcycle of chemotherapy: analysis of 854 patients from the UnitedKingdom Medical Research Council AML 10 and 12 trials.Blood 2001; 98: 1752-1759. doi: 10.1182/blood.v98.6.1752.

  15. Byun JM, Kim Y, Yoon H, Kim S, et al. Cytogenetic profiles of2806 patients with acute myeloid leukemia. Retrospectivemulticenter nationwide study. Ann Hematol 2016; 95:1223-1232. doi: 10.1007/s00277-016-2691-1.

  16. Souza-Melo CP, Brant-Campos C, Pimenta-Dutra Á, Aguirre-NetoJC, et al. Correlation between FLT3-ITD status and clinical, cellularand molecular profiles in promyelocytic acute leukemias.Leuk Res 2015; 39: 131-137. doi:10.1016/j.leukres.2014.11.010




2020     |     www.medigraphic.com